T. Rowe Price Associates’s Trevi Therapeutics TRVI Stock Holding History

T. Rowe Price Associates’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Buy	88,057 +23,354	+36%	+$340K	﹤0.01%	2105
2026 Q1	$772K	Buy	64,703 +14,430	+29%	+$162K	﹤0.01%	2264
2025 Q4	$630K	Buy	50,273 +3,414	+7%	+$39.5K	﹤0.01%	2289
2025 Q3	$429K	Buy	46,859 +8,307	+22%	+$62.3K	﹤0.01%	2428
2025 Q2	$211K	Buy	38,552 +6,390	+20%	+$39.8K	﹤0.01%	2691
2025 Q1	$203K	Buy	32,162 +6,996	+28%	+$33.4K	﹤0.01%	2632
2024 Q4	$104K	Buy	25,166 +6,119	+32%	+$19.6K	﹤0.01%	2827
2024 Q3	$64K	Hold	19,047	–	–	﹤0.01%	2897
2024 Q2	$57K	Buy	19,047 +5,486	+40%	+$15.2K	﹤0.01%	2839
2024 Q1	$47K	Buy	+13,561	New	+$30.3K	﹤0.01%	2880

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

T. Rowe Price Associates's TRVI Position: Q2 2026 in Review

T. Rowe Price Associates increased its Trevi Therapeutics (TRVI) stake by 36% in Q2 2026, buying an estimated $340K and bringing the position to 88,057 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

T. Rowe Price Associates first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

T. Rowe Price Associates held 88,057 shares of Trevi Therapeutics worth $1.64M as of Q2 2026.
T. Rowe Price Associates bought 23,354 Trevi Therapeutics shares in Q2 2026, an estimated $340K.
Trevi Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2105 holding.
T. Rowe Price Associates first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.